Tag Archives: Tev Tropin

Business, Finance, Occupation & Industry

Antares Pharma Announces Notice of Allowance for New Patent on VIBEX™ QuickShot Device

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Antares Pharma Announces Notice of Allowance for New Patent on VIBEX™ QuickShot Device

EWING, N.J.–(BUSINESS WIRE)– Antares Pharma, Inc. (NAS: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Trade Office (USPTO) on a patent application for the VIBEX™ QuickShot (QS) device, the latest advancement in its proprietary line of VIBEX™ auto-injector systems.

Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “The size and scope of our intellectual property portfolio continues to grow as we develop device technologies that will enhance the product performance of established drugs as well as new drugs in development.” Dr. Wotton continued, “We believe that many injectable drugs currently under development will be administered by self-injection once they reach the market. Our advancing technology will therefore be important for the growing number of chronic care products that can only be given by injection.”

The VIBEX™ QS device offers a dose capacity up to 1 mL and the design can be scaled for larger volumes. The device design emphasizes enhanced performance on the attributes most critical to patient success – speed, comfort and discretion. The new design also accommodates fast injection of highly-viscous drug products that stall less-powerful conventional auto-injectors. Many self-injectable biological agents currently marketed and in clinical development are formulated to be administered in a 1 mL dose volume and tend to be of higher viscosity than non-biologic injectable products.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™, a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for testosterone replacement therapy. The Company’s technology platforms include VIBEX™ disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX™ epinephrine and several other products. Antares Pharma‘s partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products …read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Antares Pharma Announces First Shipment of Commercial VIBEX™ Auto-Injector Devices to Teva

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Antares Pharma Announces First Shipment of Commercial VIBEX™ Auto-Injector Devices to Teva

EWING, N.J.–(BUSINESS WIRE)– Antares Pharma, Inc. (NAS: ATRS) today announced the first shipment of commercial-ready VIBEX™ auto-injector devices to Teva at the end of the first quarter 2013. This initial order for pre-launch quantities of the generic epinephrine auto-injector represents the first of many shipments that will take place during 2013.

Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “Today’s announcement marks yet another milestone for Antares and the successful commercial production of VIBEX™ devices is an important achievement.” Dr. Wotton continued, “Our growing and maturing development pipeline that includes OTREXUP™ for Rheumatoid Arthritis and QST for testosterone replacement therapy, is constructed around the proprietary VIBEX™ platform and this demonstrated ability to manufacture devices at a commercial scale is both a significant accomplishment for the Company and a major step forward for our own internal development programs.”

Antares entered into an exclusive license development and supply agreement under which Teva is obligated to purchase all of its epinephrine auto-injector device requirements from us. We receive a negotiated purchase price for each device sold and will receive royalties on sales of their epinephrine product. On April 26, 2012, Antares announced a settlement agreement with Meridian Medical Technologies, a Pfizer subsidiary under which Teva may launch a generic epinephrine auto-injector on June 22, 2015 or earlier under certain circumstances, subject to approval from the U. S. Food and Drug Administration.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™, a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for testosterone replacement therapy. The Company’s technology platforms include VIBEX™ disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX™ epinephrine and several other products. Antares Pharma‘s partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Antares Pharma to Host Fourth Quarter 2012 Call

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Antares Pharma to Host Fourth Quarter 2012 Call

EWING, N.J.–(BUSINESS WIRE)– Antares Pharma, Inc. (NAS: ATRS) today announced it will release its fourth quarter 2012 financial results before the market opens on Wednesday, March 13, 2013, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Paul K. Wotton, Ph.D., President and Chief Executive Officer, and Robert F. Apple, EVP, Chief Financial Officer, and President of the Parenteral Products Division, will host the call.

Interested parties may participate in the conference call by dialing 1-877-941-0844 (US) or 1-480-629-9835 (international), 5-10 minutes prior to the start of the call. A replay of the conference call will be available approximately 2 hours after the call’s conclusion through 12:00 p.m. ET (Eastern Time) on March 27, 2013 by dialing 1-800-406-7325 (US) or 1-303-590-3030 (international), and entering the access code 4600866. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares Web site at www.antarespharma.com.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™, a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for testosterone replacement therapy. The Company’s technology platforms include VIBEX™ disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX™ epinephrine and several other products. Antares Pharma‘s partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company’s corporate office and the Product Development and Commercial Group are located in Ewing, New Jersey.

…read more
Source: FULL ARTICLE at DailyFinance